Stock markets fell sharply in Europe as Middle East crisis intensifies. Photograph: EPA

European stocks fell sharply as violence in the Middle East escalated and a report showed the US economy shrank in the first quarter by the most sinc(...)

Shire shareholders deserve a higher price than US drugmaker AbbVie is offering, given the company’s growth prospects, Shire’s chief executive officer (...)

Tablets of Shire’s Adderall  are arranged in a Cambridge, Massachusetts pharmacy. The London-listed drugmaker has hired investment bank Citi as an adviser, expecting to receive takeover approaches. Photo: Bloomberg

London-listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the (...)

 Malignant melanoma  is one of the most aggressive forms of cancer, with 75 per cent of people dying within a year of diagnosis.  Photograph:  Spencer Platt/Getty Images

New research launched today in the US shows that combining two innovative treatments of advanced skin cancer leads to unprecedented one- and two-year (...)

Bristol-Myers Squibb is a global bio-pharmaceutical company specialising in innovative medicine to treat serious illness. File photograph: PA Wire

Pharmaceutical company Bristol-Myers Squibb has announced the closure of its facility at Cruiserath in Blanchardstown, west Dublin with the loss of(...)

Bristol-Myers Squibb’s quarterly sales and earnings beat Wall Street expectations, helped by cost cuts and growing sales of its treatments for cancer,(...)

GlaxoSmithKline said today European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperza(...)

For your diary

TODAYResults: Charteris.Indicators: Chinese gross domestic product (Q4); Chinese retail sales (Dec); Japanese industrial production (Nov).Other: Showc(...)

AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries. Photo: Bloomberg

AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be br(...)

AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3 billion, as it seeks to strengthen its limited range of innovative products and become a leading supplier of diabetes medicines

AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3 billion, as it seeks to strengthen its limited range (...)